Prosecution Insights
Last updated: April 19, 2026
Application No. 17/829,538

COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF

Non-Final OA §103
Filed
Jun 01, 2022
Examiner
RICCI, CRAIG D
Art Unit
1611
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Givaudan S A
OA Round
5 (Non-Final)
54%
Grant Probability
Moderate
5-6
OA Rounds
3y 3m
To Grant
99%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allow Rate
607 granted / 1131 resolved
-6.3% vs TC avg
Strong +52% interview lift
Without
With
+52.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
65 currently pending
Career history
1196
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
40.6%
+0.6% vs TC avg
§102
17.2%
-22.8% vs TC avg
§112
20.7%
-19.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1131 resolved cases

Office Action

§103
DETAILED ACTION Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 10/08/2025 has been entered. AIA Status of the Claims The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Arguments Applicant’s arguments, filed 9/25/2025, have been fully considered. As argued by Applicant, “the Applicants have now narrowed the scope of protection to the process comprising only step (b2)” and, “[w]ith reference to Section 6 of the present Office Action, the Examiner acknowledged that the subject matter of claim 25 with regards to the combination of step (a) with step (b2) is patentable” (Applicant Arguments, Page 9). The argument is unclear. It is unclear what is meant by “Section 6 of the present Office Action” and nowhere has it been indicated that “the subject matter of claim 25 with regards to the combination of step (a) with step (b2) is patentable” as argued by Applicant. In an effort to understand Applicant’s arguments, Applicant’s attorney, Alan Miller, was contacted by telephone to discuss, who indicated that since only the combination of step (a) with step (b1) was rejected, it was understood that the combination of step (a) with step (b2) would be patentable. The argument is not found persuasive. In Applicant’s Response to Restriction/Election dated 11/03/2023, Applicant elected a single method of making the compound PNG media_image1.png 140 180 media_image1.png Greyscale comprising the combination of step (a) with step (b2). Since the elected method of making the elected compound was found to be free of the art, the search was expanded as called for under current Office Markush practice to include a single additional species (M.P.E.P. § 803.02). That species was a method of preparing the following compound species PNG media_image2.png 108 267 media_image2.png Greyscale comprising the combination of step (a) with step (b2), which was rejected in the Action mailed on 11/20/2023. In Applicant’s response filed 2/06/02024, Applicant amended the claims to exclude the above non-elected compound of formula (I). Accordingly, in the Action mailed on 5/02/2024, the search was again expanded as called for under current Office Markush practice to include a single additional species (M.P.E.P. § 803.02). That species was the preparation of the following compound species PNG media_image3.png 117 222 media_image3.png Greyscale comprising the combination of step (a) with step (b1), which was MAINTAINED rejected in the Actions mailed on 11/22/2024 and 6/11/2025. Since Applicant has amended the claims to exclude step (b1), the search is again expanded as called for under current Office Markush practice to include a single additional species (M.P.E.P. § 803.02). That species was the preparation of the following compound species PNG media_image3.png 117 222 media_image3.png Greyscale comprising the combination of step (a) with step (b2). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim 25 is NEWLY rejected under 35 U.S.C. 103(a) as being unpatentable over Quellet et al (GB 2 528 480 published 1/27/2016 – provided in Applicant’s IDS submitted 6/01/2022; of record) in view of Ishida et al (US 2009/0171124; of record) and Wadsworth et al (J American Chem Soc 83:1733-1738, 1961). As amended claim 25 is drawn to a process for the preparation of a compound of formula (I), which embraces the following compound species PNG media_image3.png 117 222 media_image3.png Greyscale wherein R1 is C1 alkyl; R2 is C6 alkyl; R3-R7 are H; and X is CH2OH; the method comprising: (a) coupling a compound of formula A with a compound of formula B, thereby obtaining a compound of formula C, wherein: the compound of formula A is: PNG media_image4.png 120 106 media_image4.png Greyscale the compound of formula B is: PNG media_image5.png 57 60 media_image5.png Greyscale the compound of formula C is: PNG media_image6.png 112 137 media_image6.png Greyscale (b) contacting the compound of formula C with a phosphonate derivative F thereby obtaining a compound of formula (I), wherein: the phosphonate derivative F is: PNG media_image7.png 96 126 media_image7.png Greyscale Quellet et al teaches the instantly claimed compound of formula (I) (i.e., (2E,4Z)-4-benzylidene-2-methyldec-2-en-1-ol (Page 4, Line 16)). However, Quellet et al does not teach methods for preparing said compound. Yet, it would have been obvious to prepare the compound of Quellet et al as claimed based further on Ishida et al and Wadsworth et al as follows: FIRST, Ishida et al teach step (a) of coupling a compound of formula A with a compound of formula B, thereby obtaining a compound of formula C. In particular, Ishida et al teach coupling the compound R1-CHO (Formula I) with R2-CHO (Formula II) – wherein R1 and R2 can be “a linear or branched alkyl group having 1 to 20 carbon atoms… [and] an aromatic ring structure-containing group having 6 to 20 carbon atoms” (Paragraph 0021) and which read on instant formulas A and B – to provide PNG media_image8.png 69 158 media_image8.png Greyscale (Formula III-b) (Paragraph 0021) which reads on instant formula C. Even more specifically, Ishida et al teach: coupling the compound PNG media_image9.png 76 108 media_image9.png Greyscale (Paragraphs 0045 and 0048, formula (6), i.e., a compound of Formula I as defined by Ishida et al which reads on a compound of formula A as instantly claimed (see also Paragraph 0027: “[e]xamples of the aldehyde compounds I and II used as the raw aldehyde compound in the present invention include… benzaldehyde” – i.e., PNG media_image9.png 76 108 media_image9.png Greyscale )) with the compound PNG media_image10.png 49 90 media_image10.png Greyscale (Paragraph 0045, formula (2) i.e., a compound of Formula II as defined by Ishida et al which reads on a compound of formula B as instantly claimed) to provide PNG media_image11.png 84 163 media_image11.png Greyscale (Paragraph 0045, formula (7) which reads on a compound of formula C as instantly claimed (see also Paragraph 0050: “[e]xamples of the α,β-unsaturated aldehyde compounds produced by the condensation reaction II… include… α-methyl cinnamaldehyde” – i.e., PNG media_image11.png 84 163 media_image11.png Greyscale – as well as “a-hexyl cinnamaldehyde” – i.e., PNG media_image12.png 116 152 media_image12.png Greyscale ). And it is evident from Ishida et al that utilizing PNG media_image13.png 83 137 media_image13.png Greyscale (i.e., in place of PNG media_image10.png 49 90 media_image10.png Greyscale would provide PNG media_image12.png 116 152 media_image12.png Greyscale (see, e.g., Paragraphs 0021 and 0048-0050, formulas (8), (9) and (10), i.e., “a-hexyl cinnamaldehyde”). And SECOND, Wadsworth et al teach step (b2) of contacting a compound of formula C with a phosphonate derivative F, thereby obtaining a compound of instant formula (I). In particular, Wadsworth et al teach contacting a compound PNG media_image14.png 52 132 media_image14.png Greyscale (i.e., a compound of formula C as instantly claimed) with a compound having the following structure PNG media_image15.png 108 174 media_image15.png Greyscale (i.e., a phosphonate derivative F as instantly claimed) results in a compound having the following structure PNG media_image16.png 90 194 media_image16.png Greyscale (i.e., a compound of formula (I) as instantly claimed) via Honer-Wadsworth-Emmons (HWE) reaction (Page 1733, Column 1). As such, an ordinarily skilled artisan, desiring to synthesize the compound PNG media_image3.png 117 222 media_image3.png Greyscale taught by Quellet et al (Page 4, Line 16), would have found it obvious to contact PNG media_image12.png 116 152 media_image12.png Greyscale – the compound of formula C which also entails a compound having the general structure PNG media_image14.png 52 132 media_image14.png Greyscale – with PNG media_image17.png 162 198 media_image17.png Greyscale – the compound PNG media_image15.png 108 174 media_image15.png Greyscale which also entails a phosphonate derivative F – to provide said title compound PNG media_image3.png 117 222 media_image3.png Greyscale via Honer-Wadsworth-Emmons (HWE) reaction, based further on Wadsworth et al. In view of all of the foregoing, claim 25 is rejected as prima facie obvious. Claim Objections Claim 32 is MAINTAINED rejected as depending from a rejected base claim. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to CRAIG D RICCI whose telephone number is (571) 270-5864. The examiner can normally be reached on Monday through Thursday, and every other Friday, 7:30 am - 5:00 pm ET. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bethany Barham can be reached on (571) 272-6175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CRAIG D RICCI/Primary Examiner, Art Unit 1611
Read full office action

Prosecution Timeline

Jun 01, 2022
Application Filed
Jun 01, 2022
Response after Non-Final Action
Nov 17, 2023
Non-Final Rejection — §103
Jan 24, 2024
Response Filed
Apr 29, 2024
Final Rejection — §103
Jun 26, 2024
Request for Continued Examination
Jul 03, 2024
Response after Non-Final Action
Nov 21, 2024
Final Rejection — §103
Feb 12, 2025
Request for Continued Examination
Feb 13, 2025
Response after Non-Final Action
Jun 10, 2025
Final Rejection — §103
Sep 25, 2025
Response after Non-Final Action
Oct 08, 2025
Request for Continued Examination
Oct 09, 2025
Response after Non-Final Action
Mar 19, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12570673
C-MYC PROTEIN INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF
2y 5m to grant Granted Mar 10, 2026
Patent 12569440
SOLID FORMULATION OF A 1,2,4-OXADIAZOLE DERIVATIVE
2y 5m to grant Granted Mar 10, 2026
Patent 12569530
TANNIN-BASED ANTIPROLIFERATIVE PHARMACEUTICAL
2y 5m to grant Granted Mar 10, 2026
Patent 12552776
CRYSTALLINE FORMS
2y 5m to grant Granted Feb 17, 2026
Patent 12544356
COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT
2y 5m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

5-6
Expected OA Rounds
54%
Grant Probability
99%
With Interview (+52.3%)
3y 3m
Median Time to Grant
High
PTA Risk
Based on 1131 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month